Mirum Pharmaceuticals

Mirum Pharmaceuticals

Yahoo Finance • 13 days ago

Mirum and Incyte's zilurgisertib shows positive Phase 2 data in FOP

Shares of Mirum Pharmaceuticals (MIRM [https://seekingalpha.com/symbol/MIRM]) and Incyte (INCY [https://seekingalpha.com/symbol/INCY]) are in focus after the companies delivered positive pivotal Phase 2 data for their oral FOP candidate, z... Full story

Yahoo Finance • 24 days ago

Mirum Pharmaceuticals (MIRM) Reports Positive Phase 2b Data for Volixibat in PSC at EASL Congress

Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) is one of the best high short interest stocks with highest upside potential. On May 30, Mirum Pharmaceuticals reported positive results from its rare liver disease programs at the EASL International... Full story

Yahoo Finance • last month

Mirum Pharmaceuticals Enters Catalyst-Rich Stretch as LIVMARLI Sales and Pipeline Advance

Key Points Interested in Mirum Pharmaceuticals, Inc.? Here are five stocks we like better. LIVMARLI continues to drive Mirum’s commercial momentum, with first-quarter 2026 net sales of $114 million, up 55% year over year. The company rais... Full story

Yahoo Finance • 2 months ago

Mirum Pharmaceuticals prices $600M senior notes

* Mirum Pharmaceuticals (MIRM [https://seekingalpha.com/symbol/MIRM]) priced [https://seekingalpha.com/pr/20512564-mirum-pharmaceuticals-prices-600_0-million-convertible-senior-notes-offering-refinances-a] a private offering of $600M agg... Full story

Yahoo Finance • 2 months ago

Penn Capital Unloads 1.13 Million RealReal Shares Following Massive Stock Run-Up

Penn Capital Management Company disclosed in a May 6, 2026, SEC filing that it sold 1,130,234 shares of The RealReal (NASDAQ:REAL), an estimated $14.30 million transaction based on quarterly average pricing. What happened An SEC filing d... Full story

Yahoo Finance • 2 months ago

Mirum raises 2026 net product sales outlook to $660M-$680M as it targets year-end zilurgisertib launch

Earnings Call Insights: Mirum Pharmaceuticals (MIRM) Q1 2026 MANAGEMENT VIEW * "Based on that demand and continued performance across all brands, we are raising our full year revenue guidance to $660 million to $680 million." (CEO & Di... Full story

Yahoo Finance • 2 months ago

Mirum Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026

FOSTER CITY, Calif., April 29, 2026--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will report first quarter 2026 financial results on May 6, 2026. Mirum will also host... Full story

Yahoo Finance • 3 months ago

Prediction: Buying This Biotech Stock Today Could Set You Up for Life

Some things are inherently risky. Feeding a bear while camping and texting while driving come to mind. So does investing in biotech stocks. However, not every biotech stock is super-risky. Mirum Pharmaceuticals(NASDAQ: MIRM) is a rising s... Full story

Yahoo Finance • 3 months ago

Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026

On February 17, 2026, Boone Capital Management sold out its entire Cogent Biosciences(NASDAQ:COGT) stake, liquidating 945,042 shares previously worth $13.57 million. What happened According to an SEC filing dated February 17, 2026, Boone... Full story

Yahoo Finance • 3 months ago

This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position

On February 17, 2026, Boone Capital Management disclosed a new position in Tyra Biosciences(NASDAQ:TYRA), acquiring 398,482 shares worth $10.48 million at quarter’s end. What happened According to a Securities and Exchange Commission (SE... Full story

Yahoo Finance • 3 months ago

Hedge Fund Boone Capital Initiated a Stake in HealthEquity. Is the Stock a Buy?

What happened According to a U.S. Securities and Exchange Commission (SEC) filing dated February 17, 2026, Boone Capital Management established a new position in HealthEquity by purchasing 212,856 shares. The reported value of the transac... Full story

Yahoo Finance • 5 months ago

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., February 11, 2026--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on February 10, 2026, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of... Full story

Yahoo Finance • 7 months ago

Mirum Pharmaceuticals price target raised to $130 from $95 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $130 from $95 and keeps an Overweight rating on the shares. Mirum’s proposed acquisition of Bluejay Therapeutics for $250M in cash, $300M in stock, and $20... Full story

Yahoo Finance • 7 months ago

Mirum Pharmaceuticals To Acquire Bluejay Therapeutics In Rare Liver Disease Expansion

(RTTNews) - Mirum Pharmaceuticals (MIRM) on Monday announced that it has agreed to acquire Bluejay Therapeutics in a deal valued at $620 million in cash and stock, adding brelovitug, a late-stage monoclonal antibody for chronic hepatitis d... Full story

Yahoo Finance • 7 months ago

Penn Capital Unwinds $17.1 Million BGC Stake as Broker Posts 31% Revenue Surge

Key Points Philadelphia-based Penn Capital Management sold 1.6 million shares of BGC Group during the quarter ended September 30, leading to a net position change estimated at $17.1 million. The third-quarter transaction represented a 1.2... Full story

Yahoo Finance • 8 months ago

Mirum aims for $500M–$510M 2025 revenue as cash flow turns positive and pivotal trial readouts approach

Earnings Call Insights: Mirum Pharmaceuticals (MIRM) Q3 2025 MANAGEMENT VIEW * CEO Christopher Peetz stated that "2025 continues to be an outstanding year for Mirum" and highlighted strong commercial results, pipeline progress, and a s... Full story

Yahoo Finance • 8 months ago

The Math Shows FHLC Can Go To $79

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • 10 months ago

MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Shows High Growth Momentum and Technical Breakout Potential

MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM [https://www.chartmill.com/stock/quote/MIRM]) has become an interesting candidate for investors using a high growth momentum strategy with technical breakout analysis. This method focuses on finding c... Full story

Yahoo Finance • 10 months ago

MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Screens as a High-Growth Momentum Stock Using Minervini Trend Template

MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM [https://www.chartmill.com/stock/quote/MIRM]) has appeared as a notable candidate from a screening method that joins Mark Minervini’s Trend Template with a High Growth Momentum (HGM) rating. This two-... Full story

Yahoo Finance • 11 months ago

Mirum Pharma CEO Peetz sells $2.48 million in shares

Mirum Pharmaceuticals (NASDAQ:MIRM) Chief Executive Officer Christopher Peetz sold 40,000 shares of common stock on August 11, 2025, at a price of $62.0, totaling $2.48 million. The transaction was executed under a Rule 10b5-1 trading plan... Full story